Anti-CD47 antibodies suppress tumor growth, enhance antitumoral macrophage recruitment, and activate CD8+ T cells in multiple tumor models, including glioblastoma, where CD47 blockade reprogrammed TAMs (25, 85). Here, CD8A is linked to neoplasm.